AstraZeneca Initiates Global Phase III Trial of PD-1/TIGIT Bispecific Antibody Rilvegostomig in First-Line Metastatic Non-Squamous NSCLC

On January 3, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed,AstraZeneca(AZN.US) registered a global Phase III study (CTR20244980) of Rilvegostomig or Pembrolizumab combined with chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer.

This is a randomized, double-blind, multi-center, global, Phase III study aimed at evaluating the efficacy and safety of Rilvegostomig in combination with chemotherapy compared to Pembrolizumab in combination with chemotherapy as a first-line treatment for participants with non-squamous non-small cell lung cancer whose tumors express PD-L1 (TC≥1%). The primary endpoints are OS and PFS. A total of 250 institutions are participating in this trial, with plans to enroll 132 subjects in China and 878 subjects internationally.

Editor: Guo Mingyu